Overview of the Pharmacology of Suicide
Select a Webinar Format:

Sorry... No formats available to order at this time. Live session registrations ended at June 26, 2010 at 8:00 AM EDT, and there are no archived versions available yet. Please check back in a few days to order the archived session.

Overview of the Pharmacology of Suicide

 

Slide Presentation
Dr. Ross J. Baldessarini, MD
Director: Neuropharmacology Laboratory, Bipolar & Psychotic Disorders Program, International Consortium for Bipolar Disorders Research, and Psychopharmacology Program and Consultation Service, McLean Hospital, Harvard University

Speaker
Dr. Carlos A. Zarate, MD
Chief Experimental Therapeutics of the Mood and Anxiety Disorders Program, National Institute of Mental Health; Clinical Professor of Psychiatry and Behavioral Sciences, George Washington University

Disclosures:  Baldessarini has indicated a significant financial interest or other affiliation with the following commercial supporters of the educational presentation and manufacturer of any commercial products discussed in his session: AstraZeneca, Auritec, Biotrofix, Janssen, JDS-Noven, Lilly, Luitpold, NeuroHealing, Novartis, Pfizer, and SK-BioPharmaceutical Corporations. Zarate has no conflicts of interest to disclose. Discussion of off-label uses (using products for a purpose other than that for which it was approved by the Food and Drug Administration, or FDA) will occur during this presentation. The activity planners have no conflicts of interest to disclose.

 

Session Length
90 minutes

 

Session Objectives
Upon completion of this presentation, the participant will be able to:

1. Gain appreciation of striking advances over the past decade in knowledge of psychopharmacology as it impacts favorably or unfavorably on suicidal behavior
2. Gain appreciation of some complexities of research in this area, including regulatory policies and procedures as regards putative increases in suicidal risks with some CNS-active drugs. 
3. Gain perspective on how clinical practice and research needs to address risk of suicidal and other violent behavior as well as the broader topic of mortality associated with major psychiatric disorders. 

 

Continuing Nursing Education
1.5 contact hours. * In order to receive contact hours, you must:  Listen to the entire session, complete an evaluation, and earn a passing score on the post test before the expiration date.You will have 5 tries to earn a score of 80% or better on the post test. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. We cannot award credit unless all steps are completed.


The content of this CNE activity pertains to pharmacology. Because states' requirements may vary, contact your Board of Nursing for more information. 

 

The American Psychiatric Nurses Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

 

Originally Presented
June 26, 2010
8:00-9:30 am
Hyatt Regency Reston
Reston, VA

 

Release Date:  August 23, 2010
The contact hours for this session expire: July 1, 2013

The American Psychiatric Nurses Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.